DM, had a benign breast disease at histology or in whom Immuno-histochemistry (IHC) was inadequate were excluded from the study.
Introduction
In India, self-detected breast lumps are the most common presentation of breast cancer. [1] The prognosis and management is influenced by several factors, including the level of expression of human epidermal growth factor receptor type 2 (HER2/neu) gene; overexpression of which is reported in 15%-25% of cases in the west [2] and in up to 46.3% of cases in India. [3] HER2/neu overexpression is associated with higher cell proliferation and more neoangiogenesis, [4] leading to more aggressive tumors which may have distinct macroscopic and imaging features. [5] Identification of these could improve our understanding of biological behavior and guide management. Digital mammography (DM) is the mainstay of imaging and digital breast tomosynthesis (DBT) helps in better lesion characterization, by reducing the masking effect of overlapping tissues. [6, 7] We hypothesized that the imaging features on DM and DBT would correlate with the degree of HER2/neu expression.
Methods

Patient population
This study included consecutive patients with self-detected breast lumps who underwent breast imaging during the period from January 2016 to October 2016. Their DM and DBT images were saved and were reevaluated specifically for this study separately by two radiologists who were unaware of the cytopathology and/or histopathology findings and the original mammography report. Any patients who had had a breast intervention (e.g., core, incisional, or excisional biopsy) before This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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Breast Cancers ORIGINAL ARTICLE lesion was done. A mammographic view on either DM or DBT showing maximum lesion size was chosen for measurement of diameter. A time interval of >2 weeks was kept between the two reading sessions. In cases of the disparity between reviewers, a consensus opinion was obtained.
Immunohistochemistry analysis
For each patient, paraffin sections (4-6-μm thick) of excision specimens were assessed for HER2/neu expression using rabbit anti-human c-erbB2 oncoprotein (SP3, Dako, Denmark) after heat-induced epitope retrieval. Polymer-based technique with DAB as chromogen was employed for detection of the bound antibody (Ultra Vision Quanto HRP and DAB, Thermo Fisher Scientific). The HER2/neu expression was scored according to the ASCO 2013 HER2 test guidelines for immunohistochemical expression as 0-3+ for breast cancers. A tumor was scored as 3+ if an intense complete circumferential membrane staining was observed in >10% cells. A score of 2+ was awarded for incomplete membrane and/or weak/moderate circumferential membrane expression in >10% of invasive tumor cells or intense complete circumferential membrane staining in ≤10% of cells. A tumor was scored as 1+ when faint/barely perceptible incomplete membrane staining was noted in >10% of the invasive tumor cells. A tumor was scored as "0" when no staining was observed or it showed faint/barely perceptible incomplete membrane staining noted in ≤10% of the invasive tumor cells.
Data analysis
Relationship of DM and DBT findings with HER2/neu status was assessed using the Pearson's Chi-squared test; if one or more cells in the contingency tables had values less or equal to five, Fisher's exact test was used. Analyses were performed using Statistical Package for Social Sciences software, version 22 (SPSS-22, IBM, Chicago, IL, USA). Values of P < 0.05 were considered as statistically significant.
The study was approved by our Institutional ethics committee, and all the patients provided informed consent.
Results
Of the 100 women originally enrolled, 37 were excluded because they had a benign disease (n = 20), had undergone a prior lumpectomy (n = 10) or incision/excision biopsy (n = 5), or did not undergo IHC (n = 2). The mean age of the remaining 63 patients, whose data were analyzed, was 49.4 ± 10.6 years. There was no relation of age with HER2/neu status (P = 0.623).
Of the 63 cases analyzed, 18 had HER2/neu 0 status, 13 cases were HER2/neu 1+, and 11 were HER2/neu 2+ and 21 had HER2/neu 3+ status. There were 11 triple negative breast cancers (TNBC) with HER2-0 score.
On DM alone, predominant finding was seen as asymmetry in 12 of the 63 patients, and adjunct DBT was able to reveal underlying masses in 9, thus significantly improving the lesion visibility [ Figure 1 ].
Sixteen of the 18 HER2/neu 0 cases were seen as mass without calcification, whereas only 2 appeared as mass with calcification on both DM and adjunct DBT [ Figure 2 and Table 1 ].
7/13 HER2/neu 1+ cases were seen as mass, 3 as asymmetry, 3 as mass with calcification on DM alone. On adjunct DBT underlying masses were revealed in all 3 cases seen as asymmetry and faint amorphous calcification was noted in one of them. Hence 9/13 cases were seen as mass and 4 as mass with calcification [ Figure 3 and Table 1 ].
5/11 HER2/neu 2+ cases were seen as mass, 3 as asymmetry, 3 as mass with calcification on DM alone. On adjunct DBT underlying Lesion morphology varied with HER2/neu status significantly on both DM and DBT (P = 0.04 vs. 0.015, respectively). On DBT, HER2/neu 0 tumors mostly presented as a mass without microcalcifications (88.8%) whereas 61.9% HER2/neu 3+ tumors were masses or asymmetry with microcalcifications. All 11 TNBC with HER2-0 score, presented as masses without microcalcifications (lesion morphology -P = 0.014). In our study, no case was seen as suspicious calcification alone as our study population consisted of patients presenting with self-detected masses. Margins of mass did not vary significantly with HER2/neu scores on DM or DBT (P = 0.052 vs. 0.140 respectively), the frequency of spiculated margins increased with increasing intensity of HER2/neu positivity [ Table 1 ].
BI-RADS scores varied significantly on DBT (P =0.004), as more intense HER2/neu immunostaining was frequently assigned BI-RADS 5 score. 8/18 (44.5%) of HER2/neu 0 cases were scored as BI-RADS 5, whereas 19/21 (90.5%) HER2/neu 3+ cases were assigned BI-RADS 5 score. 7/18 (38.9%) HER2/neu 0 cases were assigned BI-RADS 4b score while none of HER2/neu 3+ cases were assigned a BI-RADS 4 b and only 2 (9.5%) were scored as 4c [ Table 1 ].
Discussion
The advent of DBT has led to a significant improvement in the visibility of mammographic abnormalities due to the reduction of obscuring effects of overlapping tissue. The individual tomosynthesis slices are likely to reveal features of lesions closer to histomorphological correlates. In an effort to explore this potential,
we undertook the study to analyze whether mammographic features differ with varying degrees of HER2/neu over-expression. The study showed that some mammographic features correlate with the intensity of HER2/neu immunostaining on IHC. i m a g i n g -r e p o r t i n g a n d d a t Adjunct DBT revealed underlying masses in a significant number of cases seen as asymmetries on DM alone, due to the reduction of the effect of superimposed soft tissue. Recent studies have observed that adjunct DBT improved characterization of malignant lesions by highlighting suspicious features. [9] Various studies have shown that DBT is superior to diagnostic mammography, especially in case of masses and also demonstrated higher sensitivity of DM plus DBT over DM alone (92% vs. 89%) where mass was the predominant finding. [10, 11] In this study, lesion morphology varied with HER2/neu status significantly on both DM and DBT. On DBT, HER2/neu 0 tumors mostly presented as noncalcified masses; whereas HER2/neu 3+ tumors were masses or asymmetries with microcalcifications. All TNBC with HER2-0 score presented as masses without microcalcifications. Previously, published studies also show that TNBC are more likely to present as noncalcified masses. [12, 13] Margins of mass did not vary significantly with HER2/neu scores on DM or DBT. Farrokh et al. [14] also showed no significant correlation between margins of masses and HER2/neu status. However, on DBT, spiculated margins were more frequently seen with increasing intensity of HER2/neu positivity in our study, demonstrating its superiority over DM. A study done by Wang et al., [15] demonstrated that in masses with microcalcifications, spiculated margins were seen in significantly more tumors having HER2/neu overexpression.
In addition, the presence or absence of microcalcifications varied significantly with HER2/neu status. HER2/neu 3+ cases were associated with microcalcifications, all of them being fine pleomorphic or fine linear branching type. In a study by Sun et al. in 2014 , the ratio of malignant calcifications was significantly high in HER2/neu positive cases.
[16] Similar findings were reported by Wang et al. in 2008 . [15] In a systematic review and meta-analysis by Elias et al. in 2014, it was found that the presence of microcalcifications increased the chance of HER2/neu overexpression, which was not dependant on the presence or absence of associated mass. [5, 14] Some studies showed a correlation specific to fine linear/branching microcalcifications. [5] The study showed that BI-RADS scores varied significantly on DBT as more intense HER2/neu immunostaining was frequently associated with BI-RADS 5 score. Previous studies have reported that the chance of a patient having HER2 overexpression was higher in cases where mammographic findings were highly suspicious for malignancy. [5] Similar results had been reported in a study by Bae et al. for Ductal carcinoma in-situ, where there was a positive correlation of BI-RADS score and Her2/neu over-expression. [17] There are some limitations in our study including a small study sample and a lack of correlation of FISH test to verify the HER2/NEU status as obtained by IHC. Morphology of the lesions may have been affected by the fact that lesions were already palpable when diagnosed. However, this may have been beneficial as well, because it is more likely to reflect the completely evolved tumor characteristics since no early intervention was done.
Conclusion
• In patients with self-detected lumps, mammographic findings may predict HER2/neu expression, which can be useful in better prognostication and management • Higher BI-RADS scores, fine pleomorphic and fine linear branching calcifications and spiculated margins of tumors are frequently associated with HER2/neu 3+ lesions • HER2/neu 1+ and HER2/neu 2+ lesions are variably associated with microcalcifications which are more often of amorphous or punctate type and rarely extensive. Thus HER2/neu 1+ and HER2/neu 2+ lesions may have distinct mammographic features, particularly related to calcification morphology and its extent. This observation needs to be investigated in larger studies.
In this patient, calculated potassium deficit was 700 meq.
Intravenous potassium chloride (20 meq/h) and oral syrup Potassium chloride 20 mL every four hourly (200 mL contain 40 meq potassium) were started and continued for 3 days.
Patient's power in upper limbs started improving by the 2 nd day, and the power in lower limbs started improving by the 3 rd day. On the fourth day, his serum potassium was 3.2 mEq/L. Power improved to Grade 4 in both upper limbs as well as lower limbs and he was able to walk.
Abiraterone was restarted after recovery in 250 mg daily dose, increasing to 1000 mg/day. He has been tolerating the dose since the past 6 months.
Abiraterone with prednisolone is a standard of care in metastatic prostate cancer.
In April 2011, the Food and Drug Administration approved androgen synthesis inhibitor abiraterone acetate in combination with low-dose prednisone, for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel. [1, 2] There are two large randomized clinical trials which demonstrated that the combination of abiraterone plus androgen deprivation therapy significantly prolongs overall survival in patients with castration-sensitive prostate cancer. [3, 4] The most common adverse reactions with Abiraterone are fatigue, backache or joint discomfort, peripheral edema, diarrhea, nausea, constipation, hypokalemia manifesting as torsades des pointes, atrial fibrillation, hypertension, glucocorticoid deficiency, increased alanine aminotransferase, aspartate aminotransferase, and cardiac disorder. [1] Abiraterone-induced severe hypokalemia is very rare and can occur without diarrhea. Severe hypokalemia leading to quadriplegia is extremely unusual. Abiraterone causes Grade 3 and Grade 4 hypokalemia (10% and 1%, respectively). [3] We believe that this is primarily due to abiraterone as he had mild diarrhea (one or two motion only), that too 3-4 days before developing quadriplegia. He had stopped the medication during diarrhea and restarted it after 3-4 days when he presented to us with quadriplegia.
Adverse effects of abiraterone such as hypertension, hypokalemia, fluid retention, and edema occur due to increase in mineralocorticoid activity resulting from CYP17 inhibition. It should be used cautiously in cases of cardiovascular disease, uncorrected hypokalemia, adrenocorticoid insufficiency, mineralocorticoid excess, and hepatic disease.
We also believe that more frequent monitoring of serum potassium is required in certain cases such as frail patients and those with diarrhea or vomiting.
To the best of our knowledge, this is the first case of abiraterone-induced severe hypokalemia leading to quadriplegia reported in literature.
Correction of hypokalemia and control of hypertension before and during treatment is mandatory. Monitoring of blood pressure and serum potassium should be done at least once a month. Rather a broad recommendation of monthly monitoring of serum potassium, we believe more aggressive monitoring of serum potassium in the selected set of patients is required.
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